Circulating Tumour Cells As a Predictive Factor for Response to Systemic Chemotherapy in Patients with Advanced Colorectal Cancer

Overview

Journal Mol Oncol

Specialties Molecular Biology
Oncology

Date 2009 Apr 23

PMID 19383356

Citations 11

Authors

Silke Lankiewicz

Silke Zimmermann

Christiane Hollmann

Tina Hillemann

Tim F Greten

Affiliations

Soon will be listed here.

Abstract

Circulating tumour cells (CTC) can be traced in patients with different types of cancer. The aim of this study was to detect CTC in patients with advanced colorectal cancer and whether CTC are still detectable after systemic chemotherapy. Blood from 34 patients with advanced colorectal cancer was analysed for the presence of CTC before chemotherapy was given and after 3 months. Eleven patients demonstrated a tumour remission after chemotherapy. In 6 cases CTC were detectable before but not after initiation of chemotherapy. Ten patients demonstrated a progression. In 5 cases CTC were detected before and after chemotherapy. Our data suggest that the detection of CTC will help to identify patients responding to chemotherapy or with a risk of a therapy failure.

Citing Articles

Circulating Tumor Cells in Colorectal Cancer: Detection Systems and Clinical Utility.

Petrik J, Verbanac D, Fabijanec M, Hulina-Tomaskovic A, ceri A, Somborac-Bacura A Int J Mol Sci. 2022; 23(21).

PMID: 36362369 PMC: 9654465. DOI: 10.3390/ijms232113582.

Clinical Significance of Circulating Tumor Cells in Gastrointestinal Carcinomas.

Konczalla L, Wostemeier A, Kemper M, Karstens K, Izbicki J, Reeh M Diagnostics (Basel). 2020; 10(4).

PMID: 32235479 PMC: 7235836. DOI: 10.3390/diagnostics10040192.

PrediCTC, liquid biopsy in precision oncology: a technology transfer experience in the Spanish health system.

Alonso-Alconada L, Barbazan J, Candamio S, Falco J, Anton C, Martin-Saborido C Clin Transl Oncol. 2017; 20(5):630-638.

PMID: 29058262 DOI: 10.1007/s12094-017-1760-9.

Early detection of poor outcome in patients with metastatic colorectal cancer: tumor kinetics evaluated by circulating tumor cells.

E Silva V, Chinen L, Abdallah E, Damascena A, Paludo J, Chojniak R Onco Targets Ther. 2016; 9:7503-7513.

PMID: 28008271 PMC: 5167467. DOI: 10.2147/OTT.S115268.

CTC enumeration and characterization: moving toward personalized medicine.

Toss A, Mu Z, Fernandez S, Cristofanilli M Ann Transl Med. 2014; 2(11):108.

PMID: 25489582 PMC: 4245508. DOI: 10.3978/j.issn.2305-5839.2014.09.06.

References

Guller U, Zajac P, Schnider A, Bosch B, Vorburger S, Zuber M . Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann Surg. 2002; 236(6):768-75; discussion 775-6. PMC: 1422643. DOI: 10.1097/00000658-200212000-00009. View

Ge H, Gong X, Tang C . Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer. 2002; 98(3):357-61. DOI: 10.1002/ijc.10224. View

Cohen S, Alpaugh R, Gross S, OHara S, Smirnov D, Terstappen L . Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2006; 6(2):125-32. DOI: 10.3816/CCC.2006.n.029. View

Wikstrand C, Hale L, Batra S, Hill M, Humphrey P, Kurpad S . Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 1995; 55(14):3140-8. View

Kang Y, Massague J . Epithelial-mesenchymal transitions: twist in development and metastasis. Cell. 2004; 118(3):277-9. DOI: 10.1016/j.cell.2004.07.011. View

Lankiewicz S, Zimmermann S, Hollmann C, Hillemann T, Greten T . Circulating tumour cells as a predictive factor for response to systemic chemotherapy in patients with advanced colorectal cancer. Mol Oncol. 2009; 2(4):349-55. PMC: 5527776. DOI: 10.1016/j.molonc.2008.09.001. View

Zhang W, Gordon M, Lenz H . Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies. Ann Med. 2007; 38(8):545-51. DOI: 10.1080/09546630601070812. View

Koch M, Kienle P, Kastrati D, Antolovic D, Schmidt J, Herfarth C . Prognostic impact of hematogenous tumor cell dissemination in patients with stage II colorectal cancer. Int J Cancer. 2006; 118(12):3072-7. DOI: 10.1002/ijc.21784. View

Molnar B, Sipos F, Galamb O, Tulassay Z . Molecular detection of circulating cancer cells. Role in diagnosis, prognosis and follow-up of colon cancer patients. Dig Dis. 2004; 21(4):320-5. DOI: 10.1159/000075355. View

10.

Pfeiffer P, Qvortrup C, Eriksen J . Current role of antibody therapy in patients with metastatic colorectal cancer. Oncogene. 2007; 26(25):3661-78. DOI: 10.1038/sj.onc.1210377. View

11.

Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A . Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351(4):337-45. DOI: 10.1056/NEJMoa033025. View

12.

Italiano A, Saint-Paul M, Caroli-Bosc F, Francois E, Bourgeon A, Benchimol D . Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications. Ann Oncol. 2005; 16(9):1503-7. DOI: 10.1093/annonc/mdi282. View

13.

Olapade-Olaopa E, Moscatello D, MacKay E, Horsburgh T, Sandhu D, Terry T . Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer. 2000; 82(1):186-94. PMC: 2363203. DOI: 10.1054/bjoc.1999.0898. View

14.

Budd G, Cristofanilli M, Ellis M, Stopeck A, Borden E, Miller M . Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006; 12(21):6403-9. DOI: 10.1158/1078-0432.CCR-05-1769. View

15.

Moscatello D, Godwin A, Ramirez G, Gunn G, Zoltick P, Biegel J . Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 1995; 55(23):5536-9. View

16.

Zieglschmid V, Hollmann C, Gutierrez B, Albert W, Strothoff D, Gross E . Combination of immunomagnetic enrichment with multiplex RT-PCR analysis for the detection of disseminated tumor cells. Anticancer Res. 2005; 25(3A):1803-10. View

17.

Nygren P, Sorbye H, Osterlund P, Pfeiffer P . Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report. Acta Oncol. 2005; 44(3):203-17. DOI: 10.1080/02841860510029798. View

18.

Lankiewicz S, Rother E, Zimmermann S, Hollmann C, Korangy F, Greten T . Tumour-associated transcripts and EGFR deletion variants in colorectal cancer in primary tumour, metastases and circulating tumour cells. Cell Oncol. 2008; 30(6):463-71. PMC: 4618564. DOI: 10.3233/clo-2008-0432. View

19.

Bralet M, Paule B, Adam R, Guettier C . Loss of epidermal growth factor receptor expression in lymph node and liver metastases of colon carcinoma. J Clin Oncol. 2005; 23(24):5844. DOI: 10.1200/JCO.2005.01.6436. View

20.

Cunningham M, Essapen S, Thomas H, Green M, Lovell D, Topham C . Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer. Int J Oncol. 2005; 27(2):317-25. View